Strides Pharma Science Limited announced the successful launch of oral Mycophenolate Mofetil (ANDA090055) to compete in this critical cardiovascular market. Entering the generics space of such a widely prescribed oral immunosuppressant offers the company a significant revenue opportunity as branded formulary exclusivity erodes.